Impax Asset Management Group plc Has $252.56 Million Position in The Cooper Companies, Inc. (NASDAQ:COO)

Impax Asset Management Group plc lowered its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 2.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,294,697 shares of the medical device company's stock after selling 65,101 shares during the quarter. Impax Asset Management Group plc owned 1.15% of Cooper Companies worth $252,559,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Covestor Ltd lifted its holdings in Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company's stock worth $28,000 after buying an additional 208 shares during the period. Innealta Capital LLC purchased a new stake in shares of Cooper Companies in the second quarter worth $25,000. Crewe Advisors LLC raised its holdings in Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company's stock valued at $30,000 after acquiring an additional 252 shares during the period. Clearstead Trust LLC purchased a new position in Cooper Companies in the 1st quarter worth approximately $36,000. Finally, Tortoise Investment Management LLC boosted its position in shares of Cooper Companies by 75.4% during the second quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company's stock worth $34,000 after acquiring an additional 169 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

COO has been the topic of several recent research reports. Morgan Stanley upped their target price on shares of Cooper Companies from $95.00 to $104.00 and gave the company an "equal weight" rating in a research report on Tuesday, September 10th. Robert W. Baird upped their target price on Cooper Companies from $118.00 to $125.00 and gave the stock an "outperform" rating in a report on Thursday, August 29th. Needham & Company LLC reiterated a "hold" rating on shares of Cooper Companies in a research note on Thursday, August 29th. Piper Sandler lifted their target price on Cooper Companies from $115.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, August 29th. Finally, Wells Fargo & Company increased their price objective on Cooper Companies from $110.00 to $115.00 and gave the company an "overweight" rating in a report on Thursday, August 29th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $117.00.

Cooper Companies Price Performance

COO traded up $0.35 on Tuesday, hitting $105.21. 638,513 shares of the company were exchanged, compared to its average volume of 1,121,140. The business's fifty day moving average is $106.99 and its 200 day moving average is $97.26. The firm has a market capitalization of $20.95 billion, a P/E ratio of 58.64, a price-to-earnings-growth ratio of 2.28 and a beta of 0.99. The Cooper Companies, Inc. has a fifty-two week low of $80.48 and a fifty-two week high of $112.38. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping analysts' consensus estimates of $0.91 by $0.05. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. During the same quarter in the prior year, the company posted $0.84 EPS. The business's revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.65 EPS for the current year.

Insider Transactions at Cooper Companies

In other news, COO Daniel G. Mcbride sold 114,992 shares of the company's stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the transaction, the chief operating officer now directly owns 44,696 shares of the company's stock, valued at approximately $4,714,534.08. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Daniel G. Mcbride sold 114,992 shares of the firm's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the transaction, the chief operating officer now owns 44,696 shares in the company, valued at $4,714,534.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Brian G. Andrews sold 24,788 shares of the business's stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the completion of the sale, the chief financial officer now owns 6,614 shares in the company, valued at $700,422.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is currently owned by corporate insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.